Close
Nordic 9Nordic 9

Monograph Capital (investor - Venture Capital)

United Kingdom monograph.bio
See something wrong or missing? Let us know
Offices:London

Monograph Capital is a life sciences venture firm. from the UK

Average round investment:59.5M USD
Average number per year:1.3
Distribution: 2025 (2)2023 (1)2021 (1)
Portfolio companies: United Kingdom Elevara MedicinesUnited Kingdom Maxion TherapeuticsUnited Kingdom Aviado Bio
Mostly invests in: United Kingdom United Kingdom (4) Pharma (4)
See the entire list

Showing 3 of 4 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Monograph Capital mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Monograph Capital

Name Criteria
Israel aMoon
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Manufacturing, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States What If Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Manufacturing, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Kairos
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Manufacturing, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Patient Square Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Manufacturing, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Germany Evotec AG
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
United States Redmile Group
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
China GT Healthcare Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Manufacturing, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland Julius Bär Group
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Manufacturing, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Cowen Healthcare Investments
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Manufacturing, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Samsara BioCapital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Top